Specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Prepn: M. S. Egbertson et al., EP 478363; M. E. Duggan et al., US 5292756 (1992, 1994 both to Merck & Co.); J. Y. L. Chung et al., Tetrahedron 49, 5767 (1993). Physicochemical properties: J. A. McCauley et al., J. Phys. D: Appl. Phys. 26, B85 (1993). Pharmacology: J. J. Lynch et al., J. Pharmacol. Exp. Ther. 272, 20 (1995). Clinical pharmacokinetics and pharmacodynamics: J. S. Barrett et al., Clin. Pharmacol. Ther. 56, 377 (1994). Clinical trials in angina: P. Théroux et al., N. Engl. J. Med. 338, 1488 (1998); H. D. White et al., ibid. 1498. Clinical comparison with abciximab, q.v., in coronary revascularization: D. J. Moliterno et al., Lancet 360, 355 (2002).
Antithrombotic; in treatment of unstable angina.
Antithrombotic; Fibrinogen Receptor Antagonist